Quick Summary
- Historic Trial Results: Pfizer’s Phase 2 FOURLIGHT-1 trial for atirmociclib met its primary endpoint — delivering a statistically significant 40% reduction in the risk of disease progression or death (HR: 0.60, p=0.0007) in HR+/HER2- metastatic breast cancer patients who had already received prior CDK4/6 inhibitor therapy.
- A Powerful Signal: Over 90% of the 264 enrolled patients had relapsed within just 3 months of their last CDK4/6 treatment one of oncology’s hardest-to-treat groups. Despite this, atirmociclib showed consistent benefit across all subgroups, with only 6.4% discontinuing due to side effects and no new safety signals identified.
Atirmociclib Phase 2 data released mark a potentially defining moment in the treatment of hormone receptor-positive metastatic breast cancer. Pfizer’s investigational CDK4 inhibitor demonstrated a statistically significant 40% reduction in the risk of disease progression or death, results that may reshape how oncologists approach second-line therapy after prior CDK4/6 inhibitor treatment.
What Is Atirmociclib? Understanding the Next-Generation CDK4 Inhibitor
Atirmociclib is an investigational oral inhibitor of cyclin-dependent kinase 4 (CDK4) a critical protein that helps regulate how cells divide. Unlike existing CDK4/6 inhibitors already approved for HR+ breast cancer (such as palbociclib, ribociclib, and abemaciclib), atirmociclib is engineered to selectively inhibit CDK4 alone. This precision targeting is designed to deliver improved efficacy and a more favorable tolerability profile.
The drug was conceptualized and discovered internally at Pfizer, and it is now being developed specifically for HR-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer the most common subtype of the disease. The atirmociclib Phase 2 data published this week represents the first randomized clinical evidence for the drug in this patient population.
The FOURLIGHT-1 Trial: Atimociclib Phase 2 Study
Design
The Phase 2 FOURLIGHT-1 study (NCT06105632) was a randomized, open-label, multicenter trial enrolling 264 adult patients across 14 countries. Participants had HR+/HER2- advanced or metastatic breast cancer that had progressed after prior CDK4/6 inhibitor-based treatment.
Trial Arms
| Arm | Regimen | Population |
|---|---|---|
| Experimental | Atirmociclib + Fulvestrant | HR+/HER2- MBC post-CDK4/6i |
| Control A | Fulvestrant alone | HR+/HER2- MBC post-CDK4/6i |
| Control B | Everolimus + Exemestane | HR+/HER2- MBC post-CDK4/6i |
The primary endpoint was progression-free survival (PFS) as assessed by investigator review. Secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DoR), and clinical benefit rate (CBR).
7 Powerful Atirmociclib Phase 2 Results from FOURLIGHT-1
The atirmociclib Phase 2 findings are remarkable for several reasons. Here are the seven results that stand out from the FOURLIGHT-1 study:
- Primary endpoint met with high statistical significance. Atirmociclib plus fulvestrant demonstrated a statistically significant and clinically meaningful improvement in PFS (p=0.0007), clearing the primary endpoint with a strong margin.
- 40% reduction in the risk of disease progression or death. The hazard ratio of 0.60 (95% CI: 0.440–0.825) translates to a 40% decrease in risk a clinically meaningful benefit in a second-line, post-CDK4/6i setting.
- Benefit consistent across all prespecified subgroups. Patients responded regardless of performance status, menopausal status, visceral disease burden, duration of prior CDK4/6 inhibitor therapy, or which prior CDK4/6 inhibitor they received.
- More than 90% of patients initiated therapy within 3 months of their last CDK4/6 treatment. This makes the results especially relevant since the trial enrolled a particularly challenging, early-relapse population.
- Manageable and well-tolerated safety profile. Only 6.4% of patients discontinued atirmociclib due to treatment-emergent adverse events a low discontinuation rate consistent with prior studies.
- No new safety signals identified. The safety profile was consistent with prior atirmociclib studies, with no unexpected adverse events emerging.
- Overall survival data maturing with ongoing follow-up. With approximately 20% of patients having experienced an OS event, OS data were not mature at the time of the primary analysis a positive sign suggesting durability of response.
Read More: Lilly’s Verzenio® Shows Significant Survival Benefit in High-Risk Early Breast Cancer
CDK4 Selectivity: The Science Behind Atirmociclib’s Potential Advantage
Existing CDK4/6 inhibitors block both CDK4 and CDK6, which can cause dose-limiting toxicities such as neutropenia (low white blood cell count). Atirmociclib is engineered to target CDK4 with high selectivity, potentially sparing CDK6 activity. Researchers believe this selectivity could deliver comparable or superior antitumor efficacy while reducing the myelosuppressive side effects associated with dual CDK4/6 inhibition.
Pfizer’s Strategic Path Forward for Atirmociclib
The positive atirmociclib Phase 2 data are not just an endpoint, they are a launching pad. Pfizer’s oncology team is using the FOURLIGHT-1 results to accelerate atirmociclib’s development across earlier and broader treatment settings:
Phase 3 in First-Line Metastatic Disease
A Phase 3 registrational study evaluating atirmociclib in the first-line metastatic setting is already underway. The rationale is compelling: if atirmociclib can produce these results after a prior CDK4/6 inhibitor, its potential in treatment-naïve patients could be even greater.
Phase 2 in Early-Stage (Neoadjuvant) Breast Cancer
A separate Phase 2 neoadjuvant study in early-stage breast cancer is generating data, with results expected to be shared at a future medical conference. Early-stage treatment has the potential for curative intent, making atirmociclib’s development in this space one of the most closely watched areas of the Pfizer oncology pipeline.
Key Takeaways: Atirmociclib Phase 2 Summary
| Parameter | Finding |
|---|---|
| Study Name | FOURLIGHT-1 (NCT06105632) |
| Phase | Randomized Phase 2 |
| Primary Endpoint | Progression-Free Survival (Investigator-assessed) |
| Hazard Ratio (PFS) | 0.60 (95% CI: 0.440–0.825) |
| P-value | 0.0007 (statistically significant) |
| Risk Reduction | 40% reduction in progression or death |
| Discontinuation Rate | 6.4% due to treatment-emergent adverse events |
| Patients Enrolled | 264 patients across 14 countries |
| OS Maturity | ~20% events not yet mature |
| Next Step | Phase 3 (first-line MBC) ongoing; neoadjuvant Phase 2 data pending |
Last Modified:
